Share on StockTwits

Fate Therapeutics (NASDAQ:FATE) Insider Peter D. Flynn unloaded 6,488 shares of the company’s stock on the open market in a transaction dated Thursday, June 12th. The shares were sold at an average price of $7.00, for a total value of $45,416.00. Following the sale, the insider now directly owns 4,039 shares of the company’s stock, valued at approximately $28,273. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of Fate Therapeutics (NASDAQ:FATE) traded down 0.14% during mid-day trading on Friday, hitting $6.98. 6,744 shares of the company’s stock traded hands. Fate Therapeutics has a 52 week low of $4.30 and a 52 week high of $13.55. The stock’s 50-day moving average is $6.82 and its 200-day moving average is $7.27. The company’s market cap is $143.2 million.

Fate Therapeutics (NASDAQ:FATE) last released its earnings data on Tuesday, May 13th. The company reported ($0.34) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.33) by $0.01. Analysts expect that Fate Therapeutics will post $-1.45 EPS for the current fiscal year.

Fate Therapeutics, Inc, is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases, including hematologic malignancies, lysosomal storage disorders and muscular dystrophies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.